This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.
Drug: Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase)
2.5mg Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) aerosolized treatment once every 24 hours for five (5) consecutive days; a total of five (5) doses
Drug: 0.9%sodium chloride
Placebo of 0.9% sodium chloride every 24 hours for five (5) consecutive days; a total of 5 doses
Inclusion Criteria:
1. Male or Female age 18 or older
2. On high flow oxygen =/> 6 liters nasal cannula (or)
3. On mechanical ventilation
4. Clinical diagnosis of COVID-19 & positive PCR test (or)
5. Clinical diagnosis of COVID-19 & negative PCR test with clinical symptoms of COVID-19
and pathognomonic lesions on a chest CT scan
Exclusion Criteria:
1. Known allergy to Pulmozyme
2. Less than 18 years of age
3. Grave condition with anticipated death within 48 hours; at the discretion of treating
physician.
4. Enrollment in another clinical trial receiving investigatory drugs
University of South Alabama
Mobile, Alabama, United States
Investigator: Jon Simmons, M.D.
Contact: 251-471-7971
jsimmons@health.southalabama.edu
Jon D Simmons, M.D.
12514459834
jdsimmons@health.southalabama.edu
Wendy Blount, RN, MSN
2514554566
wlblount@health.southalabama.edu